Halozyme Therapeutics/HALO

$45.54

1.26%
-
1D1W1MYTD1YMAX

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

Ticker

HALO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Helen Torley

Employees

373

Headquarters

San diego, United States

HALO Metrics

BasicAdvanced
$5.7B
Market cap
18.60
P/E ratio
$2.42
EPS
1.28
Beta
-
Dividend rate
$5.7B
1.28206
$46.16
$31.86
1M
6.636
5.356
844.101
844.101
17.184
966.62%
18.01%
261.68%
19.22%
18.602
6.632
32.167
13.512
22.41%
85.54%
45.79%
31.99%

What the Analysts think about HALO

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 9 analysts.
13.7% upside
High $71.00
Low $41.00
$45.54
Current price
$51.78
Average price target

HALO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
39.22% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$196M
-14.87%
Net income
$77M
-9.96%
Profit margin
39.22%
5.77%

HALO Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.67%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.74
$0.75
$0.82
$0.79
-
Expected
$0.63
$0.71
$0.83
$0.70
$0.75
Surprise
17.62%
6.04%
-0.61%
13.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Halozyme Therapeutics stock?

Halozyme Therapeutics (HALO) has a market cap of $5.7B as of May 22, 2024.

What is the P/E ratio for Halozyme Therapeutics stock?

The price to earnings (P/E) ratio for Halozyme Therapeutics (HALO) stock is 18.6 as of May 22, 2024.

Does Halozyme Therapeutics stock pay dividends?

No, Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders as of May 22, 2024.

When is the next Halozyme Therapeutics dividend payment date?

Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders.

What is the beta indicator for Halozyme Therapeutics?

Halozyme Therapeutics (HALO) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Halozyme Therapeutics stock price target?

The target price for Halozyme Therapeutics (HALO) stock is $51.78, which is 13.7% above the current price of $45.54. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Halozyme Therapeutics stock

Buy or sell Halozyme Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing